Boston Scientific (BSX)
(Delayed Data from NYSE)
$78.25 USD
+0.67 (0.86%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $78.25 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth D Momentum C VGM
Boston Scientific (BSX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$87.93 | $100.00 | $78.00 | 13.34% |
Price Target
Based on short-term price targets offered by 28 analysts, the average price target for Boston Scientific comes to $87.93. The forecasts range from a low of $78.00 to a high of $100.00. The average price target represents an increase of 13.34% from the last closing price of $77.58.
Analyst Price Targets (28)
Broker Rating
Boston Scientific currently has an average brokerage recommendation (ABR) of 1.25 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 28 brokerage firms. The current ABR compares to an ABR of 1.28 a month ago based on 25 recommendations.
Of the 28 recommendations deriving the current ABR, 23 are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 82.14% and 10.71% of all recommendations. A month ago, Strong Buy made up 80%, while Buy represented 12%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/BSX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 23 | 23 | 20 | 20 | 19 |
Buy | 3 | 3 | 3 | 3 | 3 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.25 | 1.25 | 1.28 | 1.28 | 1.29 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/5/2024 | Piper Sandler | Matthew O'Brien | Strong Buy | Strong Buy |
7/30/2024 | Daiwa America | Narumi Nakagiri | Not Available | Strong Buy |
7/26/2024 | UBS | Danielle Antalffy | Strong Buy | Strong Buy |
7/25/2024 | Not Identified | Not Identified | Hold | Hold |
7/25/2024 | Robert W. Baird & Co. | David Rescott | Strong Buy | Strong Buy |
7/25/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
7/25/2024 | Raymond James | Jayson T Bedford | Strong Buy | Strong Buy |
7/25/2024 | Needham & Company | Michael Matson | Moderate Buy | Moderate Buy |
7/25/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
7/25/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
7/25/2024 | Canaccord Genuity | William J Plovanic | Strong Buy | Strong Buy |
7/25/2024 | Wells Fargo Securities | Lawrence H Biegelsen | Strong Buy | Strong Buy |
7/24/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/16/2024 | Cowen & Co. | Joshua T Jennings | Strong Buy | Strong Buy |
7/15/2024 | BTIG | Marie Thibault | Strong Buy | Strong Buy |
7/12/2024 | Mizuho SecuritiesUSA | Anthony Petrone | Strong Buy | Strong Buy |
7/10/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/20/2024 | Truist Securities | Richard Newitter | Strong Buy | Strong Buy |
5/30/2024 | Goldman Sachs | David H Roman | Not Available | Strong Buy |
4/26/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/4/2024 | Evercore Partners | Vijay Kumar | Strong Buy | Strong Buy |
4/3/2024 | Argus Research Corp. | John M Eade | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.25 |
ABR (Last week) | 1.25 |
# of Recs in ABR | 28 |
Average Target Price | $87.93 |
LT Growth Rate | 12.60% |
Industry | Medical - Products |
Industry Rank by ABR | 97 of 253 |
Current Quarter EPS Est: | 0.58 |